Ivabradine: more precautions to protect patients with coronary artery disease because of its cardiac harms.
In 2015, the only action taken after the European review of ivabradine was the adoption of some restrictions on its use and some precautionary measures, despite the fact that this drug offers no advantages over other options and is known to have sometimes fatal cardiovascular adverse effects.